Skip to content

Real-Time Detection of Cardiotoxic Anticancer Drug by Diamond Microsensors in the Skin and Combined Monitoring of Electrocardiogram in Live Rats

FieldValue
JournalACS Sensors
Published2026-02-16
AuthorsNorzahirah Ahmad, Seishiro Sawamura, Genki Ogata, T. Ōta, Kentaro Tokudome
DOI10.1021/acssensors.5c01392

A boron-doped diamond microsensor tracked dermal doxorubicin every 10 s and recorded two concentration phases in live rats. Simultaneous electrocardiography showed that QT prolongation began before the first dermal drug peak.

The authors chose the dermis because prior evidence links dermal interstitial fluid drug levels with blood plasma. At 25 mg kg−1 intravenous doxorubicin, the representative trace began rising 1.1 min after injection. The first current peak occurred at 2.2 min and corresponded to 12.4 nM. The second phase peaked at 26 min and reached 12.0 nM. One administration therefore produced a sharp early response followed by a slower concentration maximum. Vehicle injection produced no comparable transient current. Measurements used anesthetized male hairless rats aged 10 to 12 weeks and weighing 250 to 350 g. The sensor was inserted into the dorsal dermis. Histology confirmed that the exposed tip remained in the dermis and did not reach the hypodermis. The reported traces showed the same two-phase structure, but peak timing varied among rats.

The summary across rat measurements was:

Dermal kinetic phaseTime to maximumMaximum concentration
First phase5.3 ± 3.4 min20.4 ± 12.9 nM
Second phase26.6 ± 15.4 min24.9 ± 16.3 nM

Area under the curve was 36.6 ± 10.6 nM·h. The fitted fast and slow half-lives were 2.1 ± 1.0 min and 29.0 ± 28.0 h. The large standard deviations indicate substantial between-animal variation.

The electrode used a tapered tungsten needle with a 15 to 20 μm polycrystalline boron-doped diamond tip. Its exposed reaction length measured 400 to 800 μm. Microwave plasma-assisted chemical vapor deposition used a 1% carbon-to-boron ratio, 2500 W plasma power, and 3 h deposition. A glass capillary held the needle without epoxy after argon heating at approximately 700 °C for 30 s. The authors associated prior epoxy use with nonspecific interactions that could reduce in vivo stability. The full exposed length entered the dorsal dermis, and histology confirmed that the tip remained above the hypodermis. Each measurement cycle lasted 10 s and held the electrode at 0 V for 7.5 s. It then stepped to −0.2 V, −0.6 V, and −1.5 V, with all potentials measured against Ag/AgCl. The subtraction current was the difference between the −0.6 V and −0.2 V endpoints. The −1.5 V pulse removed fouling and helped restore the hydrogen-terminated surface. Each sensor was calibrated before and after its in vivo recording. No sensor was used more than twice.

Calibration covered 1 to 30 nM doxorubicin in PBS and in PBS containing 20 mg mL−1 bovine serum albumin. The albumin curves were linear but produced smaller currents than PBS alone. They were used for in vivo conversion because dermal interstitial fluid contains albumin. Only sensors with slopes more negative than approximately −5 × 10−2 entered the in vivo tests. The selectivity panel covered essential amino acids, other endogenous molecules, and an amino acid mixture. Most samples produced oxidation currents at positive potentials but negligible reduction current. Rat plasma also produced negligible reduction current. This supports selectivity under the tested conditions. The representative in vivo limit of detection was 0.45 nM. Another dual-recording sensor had an in vivo limit of detection of 2.8 nM.

Stability and comparison with other methods

Section titled “Stability and comparison with other methods”

In one sensor, the calibration slope changed from −12.7 × 10−2 to −12.0 × 10−2 after recording. Current at 10 nM changed from −2.5 to −2.1 nA. Current at 30 nM changed from −4.9 to −4.6 nA. Across six sensors, calibration measures did not differ significantly before and after recording, with P > 0.05. Stable recordings lasted 2 to 6 h.

Microdialysis samples every 15 min and uses a collection tube approximately 1 mm in diameter. Gold aptamer sensors reported temporal resolutions of 0.5 to 1 min. An aptamer doxorubicin sensor reached 2.25 s but used a 400 μm by 15 μm probe. An enzyme-based penicillin sensor reached 5 ms but required multiple electrochemical probes. The BDD microsensor used one BDD working electrode, a 15 to 20 μm tip, and no bioreceptor coating. It also combined drug sensing with simultaneous ECG, which the paper reports as a new combination. These comparisons establish the reported resolution and geometry, not clinical superiority.

Three subdermal needle electrodes recorded ECG at 4000 Hz in lead III configuration. Baseline QT intervals ranged from 70 to 100 ms before drug administration. In the representative dual recording, QT reached 130 ms at 2.1 min. The first skin concentration peak followed this QT maximum. Across four rats, the QT maximum occurred at 2.9 ± 2.4 min. The first dermal peak occurred at 4.4 ± 4.4 min, and the second at 33.1 ± 17.1 min.

Mean ± SD values from those four rats were:

ECG parameterBaselineQT peak
Heart rate161.1 ± 22.7 bpm204.6 ± 15.7 bpm
QT interval80.6 ± 6.7 ms108.9 ± 11.5 ms
QTc interval131.9 ± 14.3 ms200.8 ± 19.4 ms
JTpeak interval63.9 ± 6.2 ms91.0 ± 10.6 ms
T peak to T end interval50.3 ± 6.4 ms73.8 ± 11.6 ms

Heart rate was the only parameter with two clear peaks, and its second rise was slower than the second skin phase. PR interval, QRS duration, and the T peak to T end divided by QTc did not change significantly. The timing supports temporal association, but it does not prove that dermal concentration caused QT prolongation. The authors therefore associate the acute QT response mainly with the first dermal phase.

LC-MS/MS analyzed suction-blister interstitial fluid for doxorubicin and doxorubicinol. Doxorubicinol stayed below the 1.5 nM quantification limit, while doxorubicin was readily detected. This argues against a major metabolite contribution to the second phase. The first phase could not be matched to mass spectrometry because collection required at least 2 h and onset varied among rats. Two explanations remained: different permeability of monomers and aggregates, or temporary obstruction by concentrated blood. The authors’ earlier cochlea study had attributed a similar early response to an injection artifact. Reducing infusion to 0.05 from 0.3 mL min−1 at 25 mg kg−1 produced a smooth monotonic response in three rats. Its maximum occurred at approximately 25 to 50 min, and the early phase appeared absent. At 10 mg kg−1 and 3 mg mL−1, three rats still showed two phases, although the first peak was smaller. Dynamic light scattering produced no usable signal below approximately 100 μM, preventing aggregate assessment at the measured nM concentrations. These tests could not distinguish the two proposed explanations. The slow-infusion result supports an injection-rate effect, but blood obstruction remains possible.

Simultaneous mass spectrometry or microdialysis validation at the same skin site was not possible. Suction sampling could not reproduce the 10 s resolution or collect enough fluid from the same narrow region. Repeated dosing was not tested because recovery required 2 to 6 h, and several rats deteriorated after long recordings. Sensor slopes changed more after recordings longer than 4.5 h. Native boron-doped diamond requires a measurable redox reaction, so weak electrochemical activity or overlapping signals limit use. Concurrently administered drugs could reduce analytical specificity. Sensor-to-sensor variation arose from tip diameter, film quality, possible boron differences, and manually set exposed lengths. Biological differences in capillary structure, anesthesia depth, and autonomic activity also affected responses. No model linked plasma, dermal interstitial fluid, and cardiomyocyte concentrations. The study therefore did not establish a dose-response relationship or causal link between skin exposure and cardiac effects. For device development, calibration repeatability, surface fouling, and signal overlap require controlled studies before wearable use. Whether other drugs produce the same biphasic profile remains untested, so the combined measurement remains a preclinical proof of concept. The authors propose awake, freely moving studies with implantable or wireless systems, but did not perform them.

The paper uses a polycrystalline boron-doped diamond film on a tapered tungsten needle with a 15 to 20 μm tip for in vivo electrochemical sensing. 6CCVD’s diamond materials catalog lists boron-doped diamond and MPCVD-grown single-crystal and polycrystalline material. The engineering support service is the route for custom fabrication questions about the needle geometry and diamond coating.

View Original Abstract

In vivo real-time detection of pharmacokinetics of systemically administrated drugs in microenvironments advance pharmacology and clinical medicine. Here, we describe an analytical platform targeting dermal interstitial fluid with a needle-type microsensor of a boron-doped diamond (BDD) electrode. A test analyte was doxorubicin, an anticancer drug that induces acute cardiotoxicity. Upon intravenous bolus injection of doxorubicin to anesthetized rats, a BDD microsensor inserted into the dermis unexpectedly detected two sequential phases of the concentration change: a first component elicited in several minutes with fast kinetics and a sharp peak, and a subsequent second response maximized from 15 min to 1 h with slow kinetics. Furthermore, the BDD microsensing system was combined with electrocardiography, visualizing a relationship between doxorubicin’s behavior in the skin and induction of QT-interval prolongation. Our approach may clarify detailed local pharmacokinetics and its correlation with pharmacodynamics and provide a prototype wearable device for next-generation drug monitoring.

  1. 2022 - Diamond Electrodes: Fundamentals and Applications [Crossref]
  2. 2005 - Diamond Electrochemistry